-
Novartis Sets Tentative Date for Sandoz Spin-Off, Targets October 4
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced October 4 of this year as the tentative date for the complete spin-off of its generics and biosimilars subsidiary, Sandoz (FRA: D8Y0). Prior to this, a crucial shareholder meeting is scheduled for September 15, where a vote will be held on the…
-
Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first half of 2023, reporting revenues of RMB 11.168 billion (USD 1.53 billion), marking a 9.19% increase year-on-year (YOY). The contribution from innovative drugs to this total was RMB 4.962 billion (USD 680 million). The company…
-
AstraZeneca’s Forxiga Gains New Indication Approval in China for Chronic Heart Failure
•
UK-based pharmaceutical major AstraZeneca plc (AZ, NASDAQ: AZN) has announced that China’s National Medical Products Administration (NMPA) has granted a new indication approval for its SGLT-2 inhibitor, Forxiga (dapagliflozin). The drug is now approved to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), or urgent HF visits…
-
Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement
•
China-based Hua Medicine (HKG: 2552) has announced the achievement of a significant development milestone for its diabetes treatment, HuaTangNing (dorzagliatin tablets, HMS5552). According to the terms of the 2020 collaboration agreement with Bayer AG (ETR: BAYN) focused on dorzagliatin, Hua is now eligible to receive a new milestone payment of…
-
MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study evaluating the first-in-class HIF-2α inhibitor Welireg (belzutifan) in previously treated advanced renal cell carcinoma (RCC) has shown statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to everolimus, meeting its primary endpoint. However,…
-
CARsgen Therapeutics Partners with Moderna to Combine CAR-T Therapy with mRNA Cancer Vaccine
•
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a collaboration agreement with US mRNA giant Moderna Inc. (NASDAQ: MRNA). The partnership aims to investigate the use of CARsgen’s investigational Claudin18.2 (CLDN18.2)-targeted chimeric antigen receptor (CAR) T-cell product candidate, CT041, in combination with Moderna’s investigational CLDN18.2 mRNA cancer vaccine. Combining…
-
Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China
•
Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd, has entered into a cooperation agreement with Taizhou Mabtech Pharmaceutical Ltd, a subsidiary of Mabpharm Ltd (HKG: 2181), focusing on the molecule CMAB009. Under the terms of the deal, Simcere Zaiming has obtained…
-
Ezisurg Medical Partners partners with Vathin for Global Disposable Endoscope strategic partnership
•
Ezisurg Medical Co., Ltd has announced a strategic partnership with Hunan Vathin Medical Instrument Co., Ltd. The collaboration aims to establish a long-term strategic cooperation on the development, commercialization, and marketing of disposable endoscope products on a global scale. Ezisurg’s Commitment to Comprehensive SolutionsEzisurg is dedicated to offering comprehensive and…
